Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $110K fell 87.3% year over year, behind the +1033.9% change in trailing-twelve-month revenue. Sequentially, it fell 99.6% from the prior quarter. Over 3 fiscal years it compounded at +111.6% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $411.29K (-98.8%) for the fiscal year ending Dec 2026, a slowdown from the +1169.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $110K-99.6% QoQ
- Last fiscal yearDec 2025
- $33.48M+1169.2% YoY
- LTMMar 2026
- $32.72M+1033.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -87.3% | -83.5% | +3.8 pp |
| 1 year | +1169.2% | -98.8% | -1268.0 pp |
| 3-year CAGR | +111.6% | -25.3% | -136.9 pp |
| 5-year CAGR | +25.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 33.48M USD
- Year-over-year change
- +1169.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.48M | +1169.2% |
| FY2024 | 2024-12-31 | 2.64M | -4.4% |
| FY2023 | 2023-12-31 | 2.76M | -21.9% |
| FY2022 | 2022-12-31 | 3.53M | +551.8% |
| FY2021 | 2021-12-31 | (782K) | — |
Revenue vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +1033.9% is the highest of 7, against a peer median of +10.2%.
- Over three fiscal years its annual growth of +111.6% compares with a peer median of -18.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $69.21M USD | +7.4% | -8.8% | |
| LTM Mar 2026 | $55.87M USD | +52.3% | — | |
| LTM Mar 2026 | $32.72M USD | +1033.9% | +111.6% | |
| LTM Mar 2026 | $16.72M USD | +138.9% | — | |
| LTM Mar 2026 | $13.86M USD | — | — | |
| LTM Mar 2026 | $11.2M USD | +13.0% | -7.0% | |
| FY2025 | €4.48M EUR | -51.3% | -28.3% | |
| LTM Mar 2026 | $225K USD | — | — | |
| LTM Mar 2026 | $59K USD | -86.6% | -85.2% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $0 USD | — | — |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding OBIO) | — | +10.2% | -18.6% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | (782K) | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | 199K | 322K | 186K | 204K | 190K |
| Gross Profit | (981K) | 3.21M | 2.57M | 2.43M | 33.29M |
| Gross Margin | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| Research & Development | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| Selling, General & Admin | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| Operating Expenses | 20.82M | 35.87M | 54.08M | 66.74M | 85.1M |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| EBITDA | (21.91M) | (33.39M) | (48.83M) | (60.72M) | (51.23M) |
| EBITDA Margin | 2801.3% | -945.0% | -1769.3% | -2301.6% | -153.0% |
| Operating Income | (21.8M) | (32.66M) | (51.51M) | (64.3M) | (51.81M) |
| Operating Margin | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Interest Income | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 927K | 0 | 0 | 0 | 1.15M |
| Other Income / Expenses | (1.22M) | (951K) | 2.39M | 3.28M | (894K) |
| Income Before Tax | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Pre-Tax Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Net Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (Basic) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| EPS (Diluted) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| Weighted Avg Shares | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
| Weighted Avg Shares (Diluted) | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.